Rupee

Eros Media World’s India Subsidiary Announces Equity Fund Raise

Retrieved on: 
Thursday, May 26, 2022
TV and Radio, Entertainment, Online, Film & Motion Pictures, Exercise, Director, Forbes, Prospectus, Bombay Stock Exchange, Media, Securities Act of 1933, Industry, Board, INR, National Stock Exchange, Person, Warrant, NYSE, Rupee, CEO, Security (finance)

Eros Media World PLC (ErosMedia, Eros" or the Company) (NYSE: ESGC), a global Indian media and entertainment company, announced today that the Board of Directors of Eros International Media Limited (EIML), its majority-owned subsidiary, recently approved EIMLs plans to raise up to an amount in Indian Rupees (INR) equal to approximately $54 million (equivalent of 4,050m INR), of equity capital via a public issuance of Convertible Warrants (the Warrants) in India, subject to EIML shareholder approval and other customary and regulatory approvals.

Key Points: 
  • Eros Media World PLC (ErosMedia, Eros" or the Company) (NYSE: ESGC), a global Indian media and entertainment company, announced today that the Board of Directors of Eros International Media Limited (EIML), its majority-owned subsidiary, recently approved EIMLs plans to raise up to an amount in Indian Rupees (INR) equal to approximately $54 million (equivalent of 4,050m INR), of equity capital via a public issuance of Convertible Warrants (the Warrants) in India, subject to EIML shareholder approval and other customary and regulatory approvals.
  • The existing Ordinary shares of EIML are listed on the Bombay Stock Exchange (the BSE) and the National Stock Exchange of India Limited (the NSE).
  • Apart from the holding company Eros WorldWide FZ LLC, the issue is subscribed by marquee investor funds such Aegis Investment Fund, Aidos India Fund Ltd, Forbes EMF, NAV Capital Emerging Star Fund, Nexpact Limited, Vespera Fund Limited and India Opportunities Growth Fund - Pinewood Strategy.
  • The Warrants issuance will provide incremental liquidity to invest in EIMLs operations, help fund future growth initiatives and improve balance sheet strength for EIML.

Viatris and Biocon Biologics Announce Launch of Interchangeable SEMGLEE® (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection

Retrieved on: 
Tuesday, November 16, 2021
TZD, Cancer, Upjohn, Security (finance), BSE, Insurance, Growth, COVID-19, Immunotherapy, Reg, Pfizer, Thiazolidinedione, Anaphylaxis, Regulation Fair Disclosure, Epidemic, Type 2 diabetes, Pandemic, Water retention, Blood, Diabetic ketoacidosis, Research, YouTube, ISIN, Cyprus Securities and Exchange Commission, Program, Patient, Adult, Private Securities Litigation Reform Act, NASDAQ, Hypoglycemia, NSE, Union, Insulin glargine, Multimedia, Rupee, Twitter, Prescription, SEC, Autoimmunity, Combination, European Free Trade Association, Adoption, Pharmacy, Caregiver, European Union, Diabetes, API, Infection, Insulin, Heart failure, LinkedIn, Hypokalemia, Medical error, Excipient, Pharmaceutical industry, Health insurance, Medical device, Fine chemical

Shreehas Tambe, dCEO, Biocon Biologics said: "At Biocon Biologics we are committed to expanding access to high-quality, affordable biologics to patients worldwide.

Key Points: 
  • Shreehas Tambe, dCEO, Biocon Biologics said: "At Biocon Biologics we are committed to expanding access to high-quality, affordable biologics to patients worldwide.
  • SEMGLEE (insulin glargine-yfgn) and Insulin Glargine (insulin glargine-yfgn), co-developed by Viatris andBiocon Biologics, are now available in the U.S. market.
  • The currently marketed non-interchangeable SEMGLEE (insulin glargine) is anticipated to be phased out by the end of the 2021 calendar year.
  • Viatris and Biocon Biologics have an exclusive collaboration for the development, manufacturing and commercialization of a broad portfolio of biosimilars and insulin analogs.

The Royal Canadian Mint Showcases Explorer John Cabot's Famous Ship to Celebrate the Passage of 70 Years Since Newfoundland and Labrador Joined Confederation

Retrieved on: 
Tuesday, March 5, 2019
Currency, Government of Canada, Bullion coins, Banking in Canada, Royal Canadian Mint, Silver coin, Coin, Canada, Commemorative coins of Canada, Rupee, Coins of the Canadian dollar

This coin features theMatthew, the sailing vessel which intrepid European explorer John Cabot sailed to Newfoundland's shores in 1497.

Key Points: 
  • This coin features theMatthew, the sailing vessel which intrepid European explorer John Cabot sailed to Newfoundland's shores in 1497.
  • 99.99% pure silver coin whose obverse also features the effigy of His Majesty King George VI, just as it appeared on the original.
  • Creativity shines on the four square coins composing the 2019 $3 Fine Silver Coin Set - The Elements.
  • The Royal Canadian Mint is the Crown corporation responsible for the minting and distribution of Canada's circulation coins.

The Royal Canadian Mint Showcases Explorer John Cabot's Famous Ship to Celebrate the Passage of 70 Years since Newfoundland and Labrador Joined Confederation

Retrieved on: 
Tuesday, March 5, 2019
Currency, Government of Canada, Bullion coins, Banking in Canada, Royal Canadian Mint, Silver coin, Coin, Canada, Commemorative coins of Canada, Rupee, Coins of the Canadian dollar

This coin features the Matthew, the sailing vessel which intrepid European explorer John Cabot sailed to Newfoundland's shores in 1497.

Key Points: 
  • This coin features the Matthew, the sailing vessel which intrepid European explorer John Cabot sailed to Newfoundland's shores in 1497.
  • 99.99% pure silver coin whose obverse also features the effigy of His Majesty King George VI, just as it appeared on the original.
  • Creativity shines on the four square coins composing the 2019 $3 Fine Silver Coin Set The Elements.
  • The Royal Canadian Mint is the Crown corporation responsible for the minting and distribution of Canada's circulation coins.